Licensing News: Breaking Licensing News, Comments and Articles. - Page: 4

BASF And Dyadic International Enter Into A Research And License Agreement

LUDWIGSHAFEN, Germany and JUPITER, Fla., May 15, 2013 /PRNewswire/ -- BASF (BAS.DE) and Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI) announced today that the two Companies have entered into a non-exclusive worldwide research and license agreement.  (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )  (Logo: http://photos.prnewswire.com/prnh/20130515/CL13970LO...

Alexza Pharmaceuticals Has A Partner In Big Pharma, Now What?

ByBio Matt:Alexza Pharmaceuticals (ALXA) recently announced that it had struck a licensing deal with Teva Pharmaceuticals (TEVA) for commercialization of Adasuve in the U.S. The licensing and supply agreement for ADASUVE (loxapine) inhalation powder will give Teva the responsibility for all U.S. commercial and clinical activities for ADASUVE, including the 3 U.S. post-approval clinical studies tha...

mariPOC® Point-of-care Immunoassay Outperforms Standard Culture in Group A Streptococcal Infection Diagnostics

TURKU, Finland, May 15, 2013 /PRNewswire/ -- ArcDia Ltd (http://www.arcdia.com). ArcDia International Ltd has released results from a clinical study comparing its rapid mariPOC® test product to the standard bacterial culture in detection of Group A streptococcal infections. The study results were presented at the GAS Infections 2013 conference, held in Rome in March, by Dr Jukka Vakkila from...

ABLYNX ANNOUNCES Q1 2013 BUSINESS UPDATE

REGULATED INFORMATION GHENT, Belgium, 15 May 2013 - Ablynx [Euronext Brussels: ABLX], the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies® for the treatment of serious diseases, today announced its business update for the three-month period ending 31st March 2013. Operating highlights Continued progress with the five Nanobody-based products in...

Algeta results for the first quarter 2013

Not Intended for US Media Oslo, Norway, 15 May 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its results for the first quarter 2013. A presentation of the results in Oslo will be webcast live from 10:00 CET and can be accessed through www.algeta.com. An international conference call will take place at 14:30 CET/08:30 EST...

Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaning

ByAvi Greenberg:Shares of Alexza Pharmaceuticals (ALXA) soared to gains of more than 50% during premarket hours on Wednesday May 8 after announcing a licensing deal with Teva Pharmaceuticals (TEVA). The stock has since fallen lower by 20%, and is currently trading with gains of 8% compared to Tuesday's close. Alexza Pharmaceuticals has seen a great year over the last 12 months, and might be a good...

Global Critical Care Market Will Reach $3.2 Billion in 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific

MarketResearchReports.Biz announces addition of new report “Global Critical Care Market to 2019” to its database. Buy the copy of this report visit - http://www.marketresearchreports.biz/analysis-details/critical-care-market-to-2019-growth-from-factor-concentrates-new-indications-and-increasing-demand-for-albumin-in-asia-pacific Albany, NY (PRWEB) May 15, 2013 GBI Research, the leading busine...

Ceapro Reports Record Financial Results in First Quarter 2013

EDMONTON, ALBERTA -- (Marketwired) -- 05/15/13 -- Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the Company") today announced record financial results for the first quarter ended March 31, 2013. FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2013 "We are very pleased to report these financial results today which include record quarterly revenues and net income, well above 2012 levels. While t...

Titan Pharmaceuticals Announces First Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/15/13 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the first quarter ended March 31, 2013. Net income for the quarter ended March 31, 2013 was approximately $6.0 million, or approximately $0.08 per share, compared to a net loss of approximately $5.2 million, or approximately $0.09 per share, for the comparable pe...

Spectrum Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Spectrum Pharmaceuticals, Inc. (SPPI) Bank of America Merrill Lynch Health Care Conference Call May 14, 2013 12:20 ET Executives Rajesh Shrotriya - Chairman, President and Chief Executive Officer Ken Keller - Executive Vice President and Chief Operating Officer Presentation Unidentified Analyst ….Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, ticker, SP...

Series C brings in $60mm for [Trevena]

GPCR-targed medicine developer [Trevena Inc.] has closed its $60mm Series C venture round. [Forest Laboraotories Inc.] invested $30mm as part of a concurrently announced licensing option agreement for Phase IIb-ready TRV027 for acute decompensated he...

UNT Health Science Center's Physical Therapy Program Achieves Accreditation

FORT WORTH, Texas, May 14, 2013 /PRNewswire-USNewswire/ -- The UNT Health Science Center's Doctor of Physical Therapy Program, which began accepting students in 2010, has achieved initial accreditation by the Commission on Accreditation for Physical Therapy Education. The program's first class, which graduates this month, will be eligible to sit for the Texas state board licensing exam. Initi...

Latteno's Subsidiary Green Cannabis Introduces Medical Marijuana Edible Products

SANTA ANA, Calif., May 14, 2013 /PRNewswire/ -- Latteno Food Corp.'s (OTCPink: LATF) wholly-owned subsidiary Green Cannabis, today announced the release of new roll-out medical marijuana edible products consisting of our own private label Peanut Butter Cup, Chocolate Bar and Chocolate Chip Cookie all made out of Cannabutter.  These are Endocannabinoid CBD Edibles: Peanut Butter Cups consist...

Natural Alternatives International, Inc. Announces Fiscal 2013 Q3 and YTD Results

SAN MARCOS, Calif., May 14, 2013 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $178,000 or $0.03 per diluted share on net sales of $15.8 million for the quarter ended March 31, 2013.  Net sales for the three months ended March 31, 201...

The Research Foundation for The State University of New York Enters Site License Agreement with 2Market Information Inc., Publisher of Technology Transfer Tactics

2Market Information Inc., publisher of Technology Transfer Tactics newsletter and producer of distance learning programs for technology transfer professionals, has announced a system-wide license agreement with The Research Foundation for The State University of New York (RF). Atlanta, Georgia (PRWEB) May 14, 2013 The agreement enables the RF to provide commercialization staff across the entire S...

Mitsubishi Tanabe: Company Profile

Mitsubishi Tanabe, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years. Return to top 50 pharma list Summary Website: Mitsubishi Headquarters: Japan Ticker Symbol: TAY (Frankfurt Stock Exchange) SEC Link: Mitsubishi Recent deal news: Mitsubishi Tanabe deal news at Current Partnering Must read report: Partnering Deals an...

Servier: Company Profile

Servier, a top pharmaceutical company, is reviewed in terms of partnering and licensing interests and activity over recent years. Return to top 50 pharma list Summary Website: Servier Headquarters: Suresnes, France Ticker Symbol: DYS (New York Stock Exchange) SEC: n/a Recent deal news: Servier deal news at Current Partnering Must read report: Partnering Deals and [...]The post Servier: Company Pro...

Emerson Ecologics Announces Four Award Recipients of the 2013 Emerson Grant Program

MANCHESTER, N.H., May 14, 2013 /PRNewswire/ -- Emerson Ecologics, LLC, the leading distributor of the highest quality professional nutritional supplements to healthcare practitioners and their patients for over 30 years, today announced the award recipients of the 2013 Emerson Grant Program. As a company dedicated to the continued emergence of integrative healthcare and wellness, the Emerson...

Derma Sciences Engages Plexus Ventures to Explore Strategic Options for DSC127 Outside the U.S.

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that it has engaged Plexus Ventures, a leading strategic advisor to the pharmaceutical, biotechnology and drug delivery industries worldwide, to explore options for DSC127 outside the U.S. The process is expected to take nine to 15 mon...

Merck KGaA: Company Profile

Merck KGaA, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years. Return to top 50 pharma list Summary Merck KGaA  is a top pharmaceutical company based in Darmstadt, Germany. The company was founded in 1668 and is the oldest pharmaceutical and chemical company in the world. [...]The post Merck KGaA: Company Profile appe...

Hearing Aid HealthCare Adds Hearing Care Blog to the Company's Website to Share Hearing Loss and Hearing Aids Tips and Advice with the Coachella Valley

Hearing Aid HealthCare is pleased to announce a new blog section on its website to share advice, research and news related to hearing loss and hearing aids. Palm Desert, CA (PRWEB) May 14, 2013 Hearing Aid HealthCare has recently added a weekly blog to the company's website to share hearing health tips and research. Every week, the Hearing Instrument Specialists at Hearing Aid HealthCare in P...

Unigene Announces First Quarter 2013 Financial Results and Provides Corporate Update

BOONTON, N.J., May 14, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE) today announced financial results for the first quarter ended March 31, 2013 and provided a corporate update on the Company's financial status and strategic initiatives.  Ashleigh Palmer, Unigene's Chief Executive Officer, commented, "2013 has been extremely challenging for Unigene.  The FDA adviso...

Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States

PHILADELPHIA, May 14, 2013 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the release of a life sciences report, "An Outlook on U.S. Biosimilar Competition," providing a comprehensive view of the challenges facing companies entering the United States biosimilar drug market a...

Evogene reports first quarter 2013 financial results

Evogene Ltd. (EVGN) announced its financial results for the first quarter ended March 31, 2013. Revenues for the first quarter of 2013 grew to $4.6 million, compared to $4.2 million for the same period in 2012. Evogene’s current revenues consist pr...

BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013

BOTHELL, Wash., May 14, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced record revenue for the first quarter of 2013 of $2.2 million, including license revenue of $0.6 mill...